Standort in Deutschland, wo man günstige und qualitativ hochwertige Kamagra Ohne Rezept Lieferung in jedem Teil der Welt zu kaufen.

Wenn das Problem der Verringerung der Potenz berührt mich persönlich war ich schockiert, dass das passiert gerade mit mir priligy Übrigens jeder leisten und gibt eine sofortige Wirkung ohne Hausarbeiten Anwendungen.

Mcintosh trail mental health/ policy no

SUBJECT: USE OF CLOZAPINE EFFECTIVE APPROVED BY: DATE: 02-27-12 (replaces 03-22-11) Executive Director Reviewed (no changes): _01-13-13___ ____________ POLICY It is the policy of McIntosh Trail MH/DD/AD Physicians to provide appropriate anti- psychotic medications to those individuals who have mental disorders which require this type of medication. Clozapine has been shown to be effective in some people who have not responded to other medications. However, potential serious adverse side effects are associated with this medication with the most serious one being agranulocytosis. As such, individuals must be carefully screened and will need to meet minimum criteria before a trial of Clozapine may begin. Also, regular monitoring of the individuals' white blood count will be a requirement of individuals on this medication. Due to the complications possible with Clozapine, it is not intended to be used as a first line treatment modality. PROCEDURE 1. To be eligible for Clozapine, the individual must meet the following criteria with any exceptions clearly and fully documented: a. Diagnosis: Individual will have a DSM-IV diagnosis of Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder. b. Demonstrated Treatment Resistance: As shown by: 1. Individuals, who despite the use of adequate doses of at least two marketed antipsychotic drugs for adequate durations of time (at least 6 week trial), have not had a satisfactory clinical response and remain substantially psychotic, or
2. Individuals with severe tardive dyskinesia who require antipsychotic medication and develop worsening of the dyskinesia when anti-
psychotics are administered, or
3. Individuals for whom it is not possible to achieve adequate doses of standard antipsychotic drugs because of severe extrapyramidal symptoms (with at least two such drugs) that are intolerable to the individual and not treatable using standard medications (i.e. c. Individual must not have a medical condition that causes low white blood count or be on any other medication which can lower white blood count (i.e. Tegretol). Individual must not have an uncontrolled seizure dis- order, active substance abuse, or significant mental retardation or a developmental disability. d. Individual must be willing to submit to required blood tests for white blood e. Be between the ages of 18 to 65, exceptions approved by Medical Director. SUBJECT: USE OF CLOZAPINE EFFECTIVE APPROVED BY: DATE: 02-27-12 (replaces 03-22-11) Executive Director Reviewed (no changes): _01-13-13___ ____________ PROCEDURE (Continued) 2. The treating physician shall discuss and educate the individual and his/her significant others regarding the benefits, side effects, and potential risks. This discussion and education shall be documented by appropriate signatures on the Clozapine Consent Form. 3. The medication shall be prescribed and monitored as per the pharmaceutical company recommendations. Individual and Treatment Team (physician and pharmacist) must be registered with the manufacturer by completing the Clozapine Patient Registry forms. 4. Baseline serum creatinine, BUN, liver profile, and CBC with differential shall be obtained prior to initiating drug therapy. Baseline EKG and current medical history and physical examination should be obtained prior to initiating Clozapine. 5. The individual must see the physician face-to-face at least once a month for the first two months of treatment; then the frequency of return visits will be at the discretion of the treating Psychiatrist, at least every 90 days. Treatment initiated by Clinical Nurse Specialist will be monitored closely by the supervising physician. 6. Individual must have prior arrangements with a Family Practice Physician, General Practitioner, or Internist who would provide medical treatment of agranulocytosis should this condition arise. The doctor's name will be contained within the Clozapine consent form and clearly identified on the individual's chart. 7. Clozapine is discontinued upon suspicion of myocarditis. Individuals with Clozapine induced myocarditis will not be rechallenged with Clozapine. 8. Serum creatinine, BUN, and liver profile shall be repeated after the initial six weeks of treatment. For those individuals continuing on the medication, these tests will be repeated at six months, twelve months, and then annually. WBC counts must be completed for four weeks after discontinuation of the medication. 9. For individuals who started Clozapine in a hospital and are discharged on Clozapine to a community program, a Clozapine Rechallenge number must be obtained by using Patient Safety Assurance Form or calling the Clozapine National Registry (generic Clozapine guidelines substituted, if appropriate). The procedures established by any regional hospital will apply for those individuals on Clozapine who are on temporary leave from the regional hospital. 10. The most current Clozapine Treatment Systems Requirements will be followed. Attachment: No. 1 - Informed Consent for Clozapine Clozapine is an antipsychotic medication which has been approved by the Federal Drug Administration for treatment of some psychiatric conditions. Clozapine has been used for years in many countries around the world, and has been found to be an effective drug for the treatment of my type of psychiatric condition. However, because of potentially serious adverse reactions, there are restrictions on the drug's use in all major countries where it is available. I understand that the possible benefits of my taking this drug are that Clozapine may prove to be more effective in controlling my psychiatric condition than any previous drug I have received and might produce fewer neurological side effects than other drugs which I might receive. In addition, if I am suffering from any abnormal movements related to my past use of antipsychotic medications, it is likely that Clozapine will help to control or eliminate these movements. If I do not have such movements, Clozapine may be less likely to cause them to develop than other medications I have had prescribed. I have been informed of possible side effects associated with this drug. Cloza- pine, like other drugs used to treat my condition, may produce drowsiness, faint- ing, decreased blood pressure, increased salivation, blurring of vision, rapid heart beat, convulsive seizure (fits), nausea and constipation. There is also a possibility of sudden death which can occur with any antipsychotic medication. Clozapine is less likely than other drugs to produce certain common side effects frequently troublesome to patients, such as stiffness, tremor, and restlessness, and may be far less likely to cause or worsen abnormal movements (tardive dyski- nesia) than standard treatments. I understand that it is impossible to predict which side effects, if any, will actually occur. I have been told that taking this medication involves the risk that this medicine may interfere with my body's ability to make white blood cells. (These are the blood cells that fight infection.) This condition is called agranulocytosis. This is not a common reaction but is a serious condition which can develop with many drugs but is considered a higher risk with Clozapine. One or two out of a hundred people may develop some form of this problem, and most will get better with proper medical treatment. Two out of a thousand patients may actually die from it. I understand that I am taking this greater potential risk with Clozapine because it may help me with psychiatric symptoms that other medicines have not helped me with in the past. The early warning signs of this reaction include feeling tired, getting a fever, having a sore throat, or getting sores that do not heal. I understand that my doctors will monitor the condition of my blood regularly with frequent blood tests. I agree to having my blood tested regularly for the duration of Clozapine treatment. I will report to my doctors immediately if I develop any signs of illness. Should I develop the condition known as agranulocytosis as a direct result of the administration of Clozapine, I understand that my primary care physician will provide for acute medical care, including hospitalization. I also understand that this would require that I immediately stop taking Clozapine, and that it is unlikely that it would be safe for me to take this drug again. I understand that Clozapine should not be taken by pregnant or nursing women or those planning to become pregnant while on the drug. I agree to tell any health care professional with whom I come in contact that I am taking Clozapine. I understand that my psychiatric condition could be treated with other medica- tions that are currently used in standard medical practice, although I have been treated with several such medications in the past and they have not been effec- tive for me. Another possibility is that I could stop taking medication altogether. However, if I do this, it is likely that I will become sicker. If I agree to take Clozapine, I will participate in interviews to assess my psy- chiatric condition and history, as well as my medical condition and history. Small samples of my blood will be taken for laboratory tests. I understand that while I am on this medication I must have weekly blood tests for six months and then every other week and pulse, blood pressure, and temperature checks in order to evaluate any effects that the drug might have on me. If I do not have a blood test, I cannot get the medication. Prior to beginning treatment with Clozapine, I will have an EKG, and a physical examination by my primary care physician. Hospital facilities and professional attention at ____________________________ Hospital will be made available if I suffer physical injury resulting directly from this treatment, and that the physician supervising my treatment, if this is necessary, will be Dr. ________________________________________________________ or one of his/her associates. (Enter name of local primary care physician and hospital.) I understand that I am under no obligation to take this medication. If I choose not to take this treatment, I will continue to have available other services which my physician and I agree that I need. If I do begin this treatment, I am also aware that I may withdraw my participation at any time without prejudice to my continued medical treatment. If I withdraw my participation, my symptoms will probably reappear. I have been given an opportunity to ask further questions and understand that I can do so at any time during the course of my treatment with Clozapine. I further understand that should I have any questions about my treatment, I may call _______________________________________ at _______________________________. _______________________________________(name of person) is knowledgeable about treatment with Clozapine, but may not be directly involved in my care. I will also be given an opportunity to discuss, in confidence, any questions I may have with a member of the Rights & Ethics Committee. This is an independent committee which monitors individuals' rights under Federal and State regulations, composed of professional staff, as well as lay members of the community not affiliated with this treatment center. Attachment 1 Page 3 Individual Name:________________________________________ CID No. ___________________ I have read the information provided above, and I am willing to take Clozapine. Individual's Name ___________________________________________________________________ (Please Print) (Date) Individual's Signature_______________________________________________________________ Family Member/Significant Other Signature____________________________________________ Relationship to Individual___________________________________________________________ Clinical Staff_______________________________________________________________________ I have fully defined and explained the treatment involved to the above individual. ______________________________________________________________ ____________________ Physician's Signature Date

Source: http://www.mctrail.org/policies/2200s/Policy2206.pdf

Program13.pub

APRIL 22-26, 2013 C ELEBRATE S CIENCE E VE NTS AND ABSTRACTS FEATURED EVENTS: • Biology Student Poster Presentations The purpose of Celebrate Science Week is to highlight the work done by SMSU’s undergraduate science students during the spring semester, as well as to celebrate the excitement and diversity of science. This week-long series of events includes poster presentat

Depression and insomnia

Depression och insomni Milton K. Erman The Scripps Research Institute and the University of California School of Medicine, La Jolla, California, USA Att humörrubbningar och sömnstörningar är nära kopplade till varandra kommer inte som någon överraskning för den som är förtrogen med medicinen, religionen eller litteraturen. Redan 400 år f. Kr. kommenterade Hippokrates i sin Book o

Copyright © 2010-2014 Internet pdf articles